BRCA1 and ovarian cancer: F79 treatment resulted in synthetic lethality in BRCA1/2-mutated breast, pancreatic, and ovarian cancer cells and displayed synergistic effect with approved drugs such as imatinib (approved for BCR-ABL1-positive leukemia) and ATRA (for PML-RAR-positive leukemia) [14].